NO333334B1 - Farmasoytisk preparat, samt slikt preparat for behandling av rhinitt - Google Patents

Farmasoytisk preparat, samt slikt preparat for behandling av rhinitt Download PDF

Info

Publication number: NO333334B1
Authority: NO; Norway
Prior art keywords: pharmaceutical mixture; weight; pharmaceutical; physiologically acceptable; acceptable salts
Prior art date: 2003-11-13

Application number

NO20044639A

Other languages

English (en)

Norwegian (no)

Other versions

NO20044639L (no

Inventor

Harald Greve

Rainer Greve

Original Assignee

Klosterfrau Mcm Vetrieb Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-13

Filing date

2004-10-27

Publication date

2013-05-06

2004-10-27 Application filed by Klosterfrau Mcm Vetrieb Gmbh filed Critical Klosterfrau Mcm Vetrieb Gmbh

2005-05-18 Publication of NO20044639L publication Critical patent/NO20044639L/no

2013-05-06 Publication of NO333334B1 publication Critical patent/NO333334B1/no

Links

206010039083 rhinitis Diseases 0.000 title claims abstract description 34
238000002360 preparation method Methods 0.000 title description 4
239000000825 pharmaceutical preparation Substances 0.000 title 1
239000000150 Sympathomimetic Substances 0.000 claims abstract description 41
150000003839 salts Chemical class 0.000 claims abstract description 39
230000001975 sympathomimetic effect Effects 0.000 claims abstract description 33
230000000694 effects Effects 0.000 claims abstract description 20
230000000699 topical effect Effects 0.000 claims abstract description 19
239000005526 vasoconstrictor agent Substances 0.000 claims abstract description 14
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
230000000069 prophylactic effect Effects 0.000 claims abstract description 7
239000000203 mixture Substances 0.000 claims description 64
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 26
229920002674 hyaluronan Polymers 0.000 claims description 25
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 24
229960003160 hyaluronic acid Drugs 0.000 claims description 24
WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims description 20
SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical group OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 16
239000011619 pantothenol Substances 0.000 claims description 15
235000020957 pantothenol Nutrition 0.000 claims description 14
GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 13
235000019161 pantothenic acid Nutrition 0.000 claims description 13
239000011713 pantothenic acid Substances 0.000 claims description 13
229940055726 pantothenic acid Drugs 0.000 claims description 13
239000000850 decongestant Substances 0.000 claims description 11
HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 claims description 10
229960001528 oxymetazoline Drugs 0.000 claims description 10
150000002148 esters Chemical class 0.000 claims description 9
CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 claims description 6
BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 claims description 6
229960000833 xylometazoline Drugs 0.000 claims description 5
239000000499 gel Substances 0.000 claims description 4
159000000000 sodium salts Chemical class 0.000 claims description 4
239000006071 cream Substances 0.000 claims description 3
MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical group C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims description 3
229960005016 naphazoline Drugs 0.000 claims description 3
239000002674 ointment Substances 0.000 claims description 3
BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical compound Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 claims description 3
229960005162 oxymetazoline hydrochloride Drugs 0.000 claims description 3
239000007921 spray Substances 0.000 claims description 3
229960000337 tetryzoline Drugs 0.000 claims description 3
239000006185 dispersion Substances 0.000 claims description 2
229960001262 tramazoline Drugs 0.000 claims description 2
QQJLHRRUATVHED-UHFFFAOYSA-N tramazoline Chemical compound N1CCN=C1NC1=CC=CC2=C1CCCC2 QQJLHRRUATVHED-UHFFFAOYSA-N 0.000 claims description 2
YGWFCQYETHJKNX-UHFFFAOYSA-N 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1h-imidazol-3-ium;chloride Chemical compound [Cl-].CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCC[NH2+]1 YGWFCQYETHJKNX-UHFFFAOYSA-N 0.000 claims 1
229960001095 xylometazoline hydrochloride Drugs 0.000 claims 1
229920002683 Glycosaminoglycan Polymers 0.000 abstract description 12
230000009471 action Effects 0.000 abstract description 7
210000004400 mucous membrane Anatomy 0.000 abstract description 7
230000002378 acidificating effect Effects 0.000 abstract description 5
230000003266 anti-allergic effect Effects 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 19
229940064707 sympathomimetics Drugs 0.000 description 19
238000001035 drying Methods 0.000 description 14
230000007794 irritation Effects 0.000 description 14
210000002850 nasal mucosa Anatomy 0.000 description 14
239000000243 solution Substances 0.000 description 13
230000002757 inflammatory effect Effects 0.000 description 12
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 10
239000013543 active substance Substances 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
229960002179 ephedrine Drugs 0.000 description 6
210000001331 nose Anatomy 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
230000001976 improved effect Effects 0.000 description 5
201000009240 nasopharyngitis Diseases 0.000 description 5
239000000126 substance Substances 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
230000006872 improvement Effects 0.000 description 4
230000008961 swelling Effects 0.000 description 4
238000009423 ventilation Methods 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
235000004866 D-panthenol Nutrition 0.000 description 2
239000011703 D-panthenol Substances 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
206010047139 Vasoconstriction Diseases 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
201000009151 chronic rhinitis Diseases 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
229960003949 dexpanthenol Drugs 0.000 description 2
DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 2
239000006196 drop Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000035876 healing Effects 0.000 description 2
150000003840 hydrochlorides Chemical class 0.000 description 2
150000002462 imidazolines Chemical class 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
238000010606 normalization Methods 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
229940083254 peripheral vasodilators imidazoline derivative Drugs 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 2
229960003908 pseudoephedrine Drugs 0.000 description 2
230000028327 secretion Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
230000025033 vasoconstriction Effects 0.000 description 2
FMCGSUUBYTWNDP-GXSJLCMTSA-N (+)-N-methylpseudoephedrine Chemical compound CN(C)[C@@H](C)[C@@H](O)C1=CC=CC=C1 FMCGSUUBYTWNDP-GXSJLCMTSA-N 0.000 description 1
FMCGSUUBYTWNDP-ONGXEEELSA-N (1R,2S)-2-(dimethylamino)-1-phenyl-1-propanol Chemical compound CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 FMCGSUUBYTWNDP-ONGXEEELSA-N 0.000 description 1
KWGRBVOPPLSCSI-PSASIEDQSA-N (1s,2r)-2-(methylamino)-1-phenylpropan-1-ol Chemical compound CN[C@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-PSASIEDQSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000218671 Ephedra Species 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
FMCGSUUBYTWNDP-UHFFFAOYSA-N N-Methylephedrine Natural products CN(C)C(C)C(O)C1=CC=CC=C1 FMCGSUUBYTWNDP-UHFFFAOYSA-N 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
229940064004 antiseptic throat preparations Drugs 0.000 description 1
210000002565 arteriole Anatomy 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229960003609 cathine Drugs 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000008602 contraction Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
229940099552 hyaluronan Drugs 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000000622 irritating effect Effects 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229940073569 n-methylephedrine Drugs 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
230000024717 negative regulation of secretion Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229960000395 phenylpropanolamine Drugs 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
230000001739 rebound effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
210000002820 sympathetic nervous system Anatomy 0.000 description 1
239000011885 synergistic combination Substances 0.000 description 1
230000009044 synergistic interaction Effects 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
230000008719 thickening Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
-1 tramazolin Chemical compound 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Pulmonology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Otolaryngology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Immunology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20044639A 2003-11-13 2004-10-27 Farmasoytisk preparat, samt slikt preparat for behandling av rhinitt NO333334B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10353690		2003-11-13
DE10356248A DE10356248A1 (de)	2003-11-13	2003-12-02	Pharmazeutische Zusammensetzung zur Behandlung von Rhinitiden

Publications (2)

Publication Number	Publication Date
NO20044639L NO20044639L (no)	2005-05-18
NO333334B1 true NO333334B1 (no)	2013-05-06

Family

ID=31969799

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20044639A NO333334B1 (no)	2003-11-13	2004-10-27	Farmasoytisk preparat, samt slikt preparat for behandling av rhinitt

Country Status (12)

Country	Link
US (2)	US20050107330A1 (da)
EP (1)	EP1532986B1 (da)
JP (1)	JP2005145963A (da)
AT (1)	ATE451934T1 (da)
CY (1)	CY1110289T1 (da)
DE (3)	DE20318634U1 (da)
DK (1)	DK1532986T3 (da)
ES (1)	ES2336668T3 (da)
NO (1)	NO333334B1 (da)
PL (1)	PL1532986T3 (da)
PT (1)	PT1532986E (da)
SI (1)	SI1532986T1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003094937A1 (en) *	2002-05-09	2003-11-20	Medigenes	A pharmaceutical composition for treatment of wounds containing blood plasma or serum
US7323184B2 (en)	2005-08-22	2008-01-29	Healagenics, Inc.	Compositions and methods for the treatment of wounds and the reduction of scar formation
DE102007052380A1 (de)	2007-10-31	2009-05-07	Bitop Ag	Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten
IT1396468B1 (it) *	2008-11-11	2012-12-14	Farma Derma Srl	Uso topico di acido ialuronico ad azione filmogena in preparati per il trattamento e profilassi di patologie delle vie respiratorie.
WO2012119261A1 (en) *	2011-03-10	2012-09-13	Biocia Inc.	Enhanced artificial mucus composition comprising hyaluronan for the treatment of rhinitis
EP2545925B1 (en)	2011-07-12	2018-02-14	Holy Stone Healthcare Co.,Ltd.	Compositions comprising hyaluronic acid for treating and preventing mucosa related diseases
NO2543357T3 (da)	2011-07-07	2018-08-18
HUE025567T2 (en) *	2011-08-19	2016-02-29	Maria Clementine Martin Klosterfrau Vertriebsges Mbh	Agents containing vasoconstrictors for combination therapy
DE102012005452A1 (de)	2011-12-30	2013-07-04	Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh	Zusammensetzung für die nasale Applikation mit verbesserter Stabilität
DE202012005650U1 (de)	2012-05-14	2013-05-15	Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh	Kombinationstherapeutikum für die Behandlung von Rhinitis
EP2985027B1 (en)	2014-08-16	2021-03-31	Church & Dwight Co., Inc.	Nasal composition comprising mixture of hyaluronic acids and saline solution
EP2985019B1 (en)	2014-08-16	2021-10-20	Church & Dwight Co., Inc.	Nasal composition having anti-viral properties
DE202014105553U1 (de)	2014-08-18	2015-08-20	Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh	Cineolhaltige Zusammensetzung für die nasale Applikation
DE202015104410U1 (de)	2015-07-06	2016-07-13	Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh	Zusammensetzung für die Behandlung von Rhinitis
DE202015104761U1 (de)	2015-09-01	2016-09-02	Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh	Cineolhaltige wässrige Zusammensetzung für die nasale Applikation
DE102017117987A1 (de)	2017-07-31	2019-01-31	Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh	Neue Zusammensetzung für die nasale Applikation
WO2019125330A2 (en) *	2017-08-10	2019-06-27	Eli̇xi̇r İlaç Araştirma Ve Geli̇şti̇rme A.Ş.	Nasal decongestant compositions comprising dexpanthenol and sodium hyaluronate
ES3039833T3 (en)	2021-09-22	2025-10-24	Jadran Galenski Laboratorij D D	An improved pharmaceutical composition for nasal use, preparation, and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1087842A (en)	1963-05-01	1967-10-18	Leo Ab	Nasal decongestive compositions
IL101056A (en) *	1992-02-24	1997-03-18	Res & Dev Co Ltd	Composition for nasal treatment
JPH0717870A (ja)	1993-06-29	1995-01-20	Toshiko Yamamoto	トローチ剤
US5624915A (en) *	1993-08-04	1997-04-29	Patent Biopharmaceutics, Inc.	Hyaluronic acid-urea pharmaceutical compositions and uses
DE19549421C2 (de)	1995-11-10	1999-11-18	Klosterfrau Mcm Vetrieb Gmbh	Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden
DE19541919C2 (de) *	1995-11-10	1997-11-20	Klosterfrau Mcm Vetrieb Gmbh	Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden
DE10064219B9 (de)	2000-12-22	2009-02-12	Nasalis Pain Relief International Gmbh	Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
CA2441352C (en) *	2001-02-15	2010-05-25	Access Pharmaceuticals, Inc.	Liquid formulations for the prevention and treatment of mucosal diseases and disorders
DE10161110A1 (de)	2001-12-12	2003-06-26	Ursapharm Arzneimittel Gmbh	Pharmazeutische Zusammensetzung zur ophthalmologischen und rhinologischen Anwendung
WO2004000272A1 (en) *	2002-06-20	2003-12-31	Novartis Consumer Health S.A.	Nasal compositions comprising a mucopolysaccharide and propylene glycol

2003
- 2003-12-02 DE DE20318634U patent/DE20318634U1/de not_active Expired - Lifetime
- 2003-12-02 DE DE10356248A patent/DE10356248A1/de not_active Ceased
2004
- 2004-10-16 PT PT04024727T patent/PT1532986E/pt unknown
- 2004-10-16 SI SI200431332T patent/SI1532986T1/sl unknown
- 2004-10-16 DK DK04024727.2T patent/DK1532986T3/da active
- 2004-10-16 DE DE502004010514T patent/DE502004010514D1/de not_active Expired - Lifetime
- 2004-10-16 EP EP04024727A patent/EP1532986B1/de not_active Expired - Lifetime
- 2004-10-16 PL PL04024727T patent/PL1532986T3/pl unknown
- 2004-10-16 ES ES04024727T patent/ES2336668T3/es not_active Expired - Lifetime
- 2004-10-16 AT AT04024727T patent/ATE451934T1/de active
- 2004-10-27 NO NO20044639A patent/NO333334B1/no not_active IP Right Cessation
- 2004-11-08 JP JP2004324021A patent/JP2005145963A/ja active Pending
- 2004-11-08 US US10/984,628 patent/US20050107330A1/en not_active Abandoned
2010
- 2010-02-12 CY CY20101100148T patent/CY1110289T1/el unknown
2011
- 2011-06-10 US US13/157,702 patent/US20110245202A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO20044639L (no)	2005-05-18
HK1080284A1 (zh)	2006-04-21
PT1532986E (pt)	2010-02-18
PL1532986T3 (pl)	2010-05-31
EP1532986A3 (de)	2005-07-20
US20110245202A1 (en)	2011-10-06
EP1532986B1 (de)	2009-12-16
CY1110289T1 (el)	2015-01-14
DE502004010514D1 (de)	2010-01-28
SI1532986T1 (sl)	2010-04-30
EP1532986A2 (de)	2005-05-25
ATE451934T1 (de)	2010-01-15
DE20318634U1 (de)	2004-02-26
ES2336668T3 (es)	2010-04-15
DE10356248A1 (de)	2005-06-23
DK1532986T3 (da)	2010-04-06
US20050107330A1 (en)	2005-05-19
JP2005145963A (ja)	2005-06-09

Legal Events

Date	Code	Title	Description
2018-05-28	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US20110245202A1 (en)	2011-10-06	Pharmaceutical composition for the treatment of rhinitis
US5801199A (en)	1998-09-01	Pharmaceutical composition for treating acute rhinitis
CA2807084C (en)	2018-05-22	Preservative free brimonidine and timolol solutions
CN103747786A (zh)	2014-04-23	比马前列素和溴莫尼定的固定剂量组合
NO177525B (no)	1995-06-26	Fremgangsmåte for fremstilling av et kombinert anti-inflammatorisk preparat
JP7199146B2 (ja)	2023-01-05	ブリモニジン及びチモロールの固定用量合剤
JP2021102626A5 (da)	2022-03-04
KR101585868B1 (ko)	2016-01-22	브래딘키닌 길항제 및 히알루론산을 함유하는 약제학적 조성물, 및 그의 용도
DE102008036725B4 (de)	2021-01-28	Pharmazeutische Zusammensetzung für die nasale Applikation
EP3664818B1 (en)	2023-11-29	Nasal decongestant compositions comprising menthol, dexpanthenol and sodium hyaluronate
RU2019136633A (ru)	2021-06-17	Лечение глаукомы
US20070042951A1 (en)	2007-02-22	Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides
CN118217243A (zh)	2024-06-21	一种增效防腐且兼顾低刺激性的右美托咪定鼻喷剂
HK1080284B (en)	2010-04-09	Pharmaceutical composition for treatment of rhinitis
JP5957517B2 (ja)	2016-07-27	結膜弛緩症治療用の点眼薬
RU2657419C1 (ru)	2018-06-13	Фармацевтическая композиция для назального применения
WO2021236671A1 (en)	2021-11-25	Low-dose carbachol compositions and methods for treatment of night vision disturbance
WO2015031183A1 (en)	2015-03-05	Compositions and methods for the treatment of nasal conditions
US11033513B2 (en)	2021-06-15	Eye drops for treatment of irritation not due to infection
JP2002322060A (ja)	2002-11-08	粘膜適用組成物
JPWO1999018969A1 (ja)	2000-05-16	高眼圧症あるいは縁内障の治療用組成物